Compare Ascendis Pharma A/S (ASND) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Capri Holdings Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Capri Holdings Ltd trades at $18.04 (market cap $2.07B). The key difference: Ascendis Pharma A/S is far larger — about 8.6× Capri Holdings Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | CPRI | |
|---|---|---|
Market Cap | $17.74B | $2.07B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $27.66 |
52-Week Low | $163.32 | $16.79 |
Enterprise Value | $18.11B | $3.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CPRI trades at $18.04, down 0.22% with bearish technical signals. The company reported mixed Q4 2026 results with an EPS beat but revenue challenges, while showing a net loss of $1.18 billion in 2025. Analyst consensus is divided with a $23.33 price target, and recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo brands.
The outlook hinges on successful execution of brand revamps and cost controls. Key risks include luxury demand volatility and high debt, but current valuation metrics like P/S of 0.62 may offer value if the turnaround gains traction. Institutional sentiment is cautiously optimistic with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
